{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:03:20Z","timestamp":1792461800362,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.069","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T02:08:13Z","timestamp":1527127693000},"page":"3926-3936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae"],"prefix":"10.1016","volume":"36","author":[{"given":"Mar\u00eda Victoria","family":"Humbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Christodoulides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.069_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2018.05.069_b0010","doi-asserted-by":"crossref","first-page":"iv63","DOI":"10.1136\/sextrans-2013-051225","article-title":"Vaccine research for gonococcal infections: where are we?","volume":"89","author":"Jerse","year":"2013","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2018.05.069_b0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14712598.2015.993375","article-title":"Glycoconjugate vaccines: an update","volume":"15","author":"Vella","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2018.05.069_b0020","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1093\/cid\/civ594","article-title":"The evolution of the meningitis vaccine project","volume":"61","author":"Tiffay","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.069_b0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba(R)): a review in active immunization against invasive meningococcal group B disease in individuals aged 10\u201325 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs: Clin Immunother, Biopharm Gene Therapy"},{"key":"10.1016\/j.vaccine.2018.05.069_b0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","article-title":"Clinical experience with the meningococcal B vaccine, Bexsero((R)): prospects for reducing the burden of meningococcal serogroup B disease","volume":"34","author":"Watson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.069_b0035","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.069_b0040","doi-asserted-by":"crossref","unstructured":"Ladhani SN, Borrow R, Andrews NJ. Growing evidence supports 4CMenB effectiveness. Lancet Infect Dis. 2018:Jan 19. pii: S1473-3099(18)30051-3. http:\/\/doi.org\/10.1016\/S1473-3099(18)-3.","DOI":"10.1016\/S1473-3099(18)30051-3"},{"key":"10.1016\/j.vaccine.2018.05.069_b0045","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.EI10-0009-2015","article-title":"Antimicrobial resistance expressed by neisseria gonorrhoeae: a major global public health problem in the 21st century","volume":"4","author":"Unemo","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2018.05.069_b0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-micro-090816-093530","article-title":"Neisseria gonorrhoeae: drug resistance, mouse models, and vaccine development","volume":"71","author":"Rice","year":"2017","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.069_b0055","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/CVI.00230-16","article-title":"Summary and recommendations from the national institute of allergy and infectious diseases (NIAID) workshop \u201cGonorrhea Vaccines: the Way Forward\u201d","volume":"23","author":"Wetzler","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.05.069_b0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s000180050299","article-title":"Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts","volume":"55","author":"Gothel","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2018.05.069_b0065","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1586\/14760584.2015.1095638","article-title":"Vaccine potential of bacterial macrophage infectivity potentiator (MIP)-like peptidyl prolyl cis\/trans isomerase (PPIase) proteins","volume":"14","author":"Humbert","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.05.069_b0070","doi-asserted-by":"crossref","first-page":"e1002027","DOI":"10.1371\/journal.ppat.1002027","article-title":"Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival","volume":"7","author":"Echenique-Rivera","year":"2011","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.vaccine.2018.05.069_b0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2016.06.020","article-title":"Inhibitors of macrophage infectivity potentiator-like PPIases affect neisserial and chlamydial pathogenicity","volume":"48","author":"Reimer","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.vaccine.2018.05.069_b0080","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/IAI.01815-14","article-title":"Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins","volume":"83","author":"Bielecka","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.069_b0085","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1128\/IAI.05019-11","article-title":"The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate","volume":"79","author":"Hung","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.069_b0090","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2958.2005.04859.x","article-title":"Ng-MIP, a surface-exposed lipoprotein of Neisseria gonorrhoeae, has a peptidyl-prolyl cis\/trans isomerase (PPIase) activity and is involved in persistence in macrophages","volume":"58","author":"Leuzzi","year":"2005","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.069_b0095","first-page":"167","article-title":"Molecular analysis of two novel Neisseria gonorrhoeae virulent components: the macrophage infectivity potentiator and the outer membrane protein A","volume":"33","author":"Starnino","year":"2010","journal-title":"New Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.069_b0100","first-page":"257","article-title":"Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide","volume":"40","author":"Zollinger","year":"1983","journal-title":"InfectImmun"},{"key":"10.1016\/j.vaccine.2018.05.069_b0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.069_b0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2013.02.007","article-title":"Development of a large scale human complement source for use in bacterial immunoassays","volume":"391","author":"Brookes","year":"2013","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.05.069_b0115","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1128\/IAI.00701-09","article-title":"Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates","volume":"77","author":"Williams","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.069_b0120","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1099\/13500872-141-4-913","article-title":"Effect of sialylation of Neisseria gonorrhoeae on recognition and complement mediated killing by monoclonal antibodies directed against different outer membrane antigens","volume":"141","author":"de la Paz","year":"1995","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2018.05.069_b0125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1099\/00221287-99-2-333","article-title":"The surface properties of Neisseria gonorrhoeae: isolation of the major components of the outer membrane","volume":"99","author":"Heckels","year":"1977","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.069_b0130","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/IAI.01424-06","article-title":"Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant","volume":"75","author":"Williams","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.069_b0135","doi-asserted-by":"crossref","first-page":"e66536","DOI":"10.1371\/journal.pone.0066536","article-title":"Mutant native outer membrane vesicles combined with a serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa","volume":"8","author":"Pajon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.05.069_b0140","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1046\/j.1365-2958.2001.02463.x","article-title":"The recX gene potentiates homologous recombination in Neisseria gonorrhoeae","volume":"40","author":"Stohl","year":"2001","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.069_b0145","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1099\/00221287-139-8-1729","article-title":"Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide","volume":"139","author":"Christodoulides","year":"1993","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.069_b0150","doi-asserted-by":"crossref","first-page":"e0160403","DOI":"10.1371\/journal.pone.0160403","article-title":"Vaccine potential and diversity of the putative Cell Binding Factor (CBF, NMB0345\/NEIS1825) protein of Neisseria meningitidis","volume":"11","author":"Humbert","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.05.069_b0155","doi-asserted-by":"crossref","first-page":"e1003559","DOI":"10.1371\/journal.ppat.1003559","article-title":"Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection","volume":"9","author":"Gulati","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.05.069_b0160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/1471-2105-11-595","article-title":"BIGSdb: scalable analysis of bacterial genome variation at the population level","volume":"11","author":"Jolley","year":"2010","journal-title":"Bmc Bioinform"},{"key":"10.1016\/j.vaccine.2018.05.069_b0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0167-7012(01)00364-5","article-title":"A one-step method for genetic transformation of non-piliated Neisseria meningitidis","volume":"49","author":"Bogdan","year":"2002","journal-title":"J Microbiol Meth"},{"key":"10.1016\/j.vaccine.2018.05.069_b0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1128\/IAI.00751-12","article-title":"Phosphoethanolamine residues on the lipid A moiety of Neisseria gonorrhoeae lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing","volume":"81","author":"Lewis","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.069_b0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.05.069_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines5010006","article-title":"Harnessing nanoparticles for immunomodulation and vaccines","volume":"5","author":"Gomes","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2018.05.069_b0185","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.069_b0190","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.addr.2017.05.003","article-title":"Designer outer membrane vesicles as immunomodulatory systems - reprogramming bacteria for vaccine delivery","volume":"114","author":"Gnopo","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2018.05.069_b0195","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/227382a0","article-title":"Gonococci in urethral exudates possess a virulence factor lost on subculture","volume":"227","author":"Ward","year":"1970","journal-title":"Nature"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T11:08:02Z","timestamp":1717240082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18307114"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}